# Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis

> **NCT05863364** · NA · UNKNOWN · sponsor: **Xin Zeng** · enrollment: 150 (estimated)

## Conditions studied

- Decompensated Cirrhosis

## Interventions

- **DRUG:** Low-dose of Rifaximin
- **DRUG:** Conventional dose of Rifaximin

## Key facts

- **NCT ID:** NCT05863364
- **Lead sponsor:** Xin Zeng
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863364, "Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05863364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*